Evolving Approaches to Early-Stage Drug Discovery

描述（由申请人提供）：本提案请求支持由克雷格W.林德斯利和琳达布雷迪，这将是在雪鸟，犹他州举行，从2011年4月3日至7日。本次会议将涵盖药物发现科学家面临的挑战和机遇的多个方面，包括以下内容：1）在资源有限的环境中早期发现的多种方法; 2）学术界临床前药物发现的演变; 3）NIH分子图书馆探针中心网络（MLPCN）的药物先导和靶标验证的演变; 4）资助早期或风险项目; 5）程序的外部许可;和6）生物标志物和成像的进步，以实现目标选择和快速的去/不去决定。会议的目标是汇集所有这些领域的专家，提出调查结果，分享当前的理解和假设，并促进对这些主题的批判性讨论。这将是第一次将来自制药行业、生物技术、学术界和NIH的药物发现科学家聚集在一起的会议--每个人都有独特的使命和方法--并为分享各自的经验提供一个论坛。此外，本次会议与Keystone研讨会会议的共同地点将大大增强跨学科互动的机会，该研讨会会议的主题是“来自错误的药物：明天的抗炎药物”。 公共卫生相关性：制药行业正面临着大规模的人员流失、合并以及后期临床试验的失败，而与此同时，学术药物发现团体正在大量涌现，并具有提供药物开发候选药物的潜力。Keystone研讨会关于早期药物发现方法的演变会议将有助于巩固该领域，推进早期药物发现的科学，并向生物医学界通报有关资源，以便通过采用概念和策略来降低药物发现工作的风险并最大限度地提高成功机会，从而更快地开发针对困难，高风险目标的治疗方法。

DESCRIPTION (provided by applicant): This proposal requests support for a Keystone Symposia meeting entitled Evolving Approaches to Early-Stage Drug Discovery, organized by Craig W. Lindsley and Linda Brady, which will be held in Snowbird, Utah from April 3 - 7, 2011. This meeting will cover multiple aspects of the challenges and opportunities facing drug discovery scientists, including the following: 1) diverse approaches to early stage discovery in a resource- constrained environment; 2) evolution of preclinical drug discovery in academia; 3) evolution of drug leads and target validation from the NIH Molecular Libraries Probe Centers Network (MLPCN); 4) funding early stage or risky programs; 5) external licensing of programs; and 6) advances in biomarkers and imaging to enable target selection and rapid go/no go decisions. The meeting goals are to bring together experts in all of these areas, present findings and share current understanding and hypotheses, and foster critical discussion of these topics. This will be the first meeting to bring together drug discovery scientists from the pharmaceutical industry, biotech, academia, and the NIH - each with unique missions and approaches - and to provide a forum for sharing their respective experiences. Furthermore, opportunities for interdisciplinary interactions will be significantly enhanced by the co-location of this meeting with the Keystone Symposia meeting on Drugs from Bugs: The Anti-Inflammatory Drugs of Tomorrow. PUBLIC HEALTH RELEVANCE: The pharmaceutical industry is facing massive attrition, mergers as well as failures in late clinical trials while, at the same time, academic drug discovery groups are emerging in greater numbers and with promising capabilities to deliver drug development candidates. The Keystone Symposia meeting on Evolving Approaches to Early-Stage Drug Discovery will serve to consolidate the field, advance the science of early stage drug discovery, and inform the biomedical community about resources to more rapidly develop therapeutics for difficult, high-risk targets by employing concepts and strategies to de-risk drug discovery efforts and maximize chances for success.